P138 Prior high dose IL-2 therapy (HDIL2) may improve the outcome of sunitinib (Su) treatment (tx) in patients (pts) with metastatic renal cell carcinoma (mRCC)

Autor:	Maya Gottfried, Keren Rouvinov, Eliahu Gez, Daniel Keizman, Avishay Sella, Hans J. Hammers, Michael A. Carducci, Avivit Peer, Mario A. Eisenberger, V. Neiman, Wilmosh Mermershtain, Henry Hayat, V. J. Sinibaldi, Raanan Berger, Eli Rosenbaum, David Sarid
Rok vydání:	2014
Předmět:	Il-2 therapy medicine.medical_specialty Sunitinib Renal cell carcinoma business.industry Urology medicine In patient medicine.disease business medicine.drug
Zdroj:	European Urology Supplements. 13:161
ISSN:	1569-9056
DOI:	10.1016/s1569-9056(14)61361-0
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f5e6e31dca7b66f5131abd5ee0bd7c3f https://doi.org/10.1016/s1569-9056(14)61361-0 Zobrazit plný text záznamu Full Text from ScienceDirect